Cargando…

Post-hoc analysis of injection-site reactions following vaccination with quadrivalent human papillomavirus vaccine in Japanese female clinical trial participants

AIM: The quadrivalent human papillomavirus (4vHPV) vaccine has demonstrated efficacy and immunogenicity and was generally well tolerated in clinical trials conducted in Japan. We report a detailed safety analysis of injection-site reactions in female Japanese 4vHPV clinical trial participants. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murata, Shinya, Shirakawa, Masayoshi, Sugawara, Yoshie, Shuto, Michiko, Sawata, Miyuki, Tanaka, Yoshiyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472855/ https://www.ncbi.nlm.nih.gov/pubmed/32827835 http://dx.doi.org/10.1016/j.pvr.2020.100205

Ejemplares similares

Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028)
por: Ishihara, Yasunori, et al.
Publicado: (2023)

Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study
por: Murata, Shinya, et al.
Publicado: (2023)

Immunogenicity, safety, and tolerability of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young Japanese adults
por: Kishino, Hiroyuki, et al.
Publicado: (2018)

The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia
por: Kosen, Soewarta, et al.
Publicado: (2017)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2017)

The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand
por: Termrungruanglert, Wichai, et al.
Publicado: (2021)

Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study
por: Leval, Amy, et al.
Publicado: (2013)

The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia
por: Uusküla, Anneli, et al.
Publicado: (2013)

Correction: Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2018)

Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain)
por: Hernandez-Aguado, Juan J., et al.
Publicado: (2022)

A case of acute disseminated encephalomyelitis following human papillomavirus quadrivalent vaccination
por: Lee, Mina, et al.
Publicado: (2022)

1050 Evaluation of syncope and related events following vaccination with quadrivalent human papillomavirus vaccine (2006-2013)
por: Lievano, Fabio, et al.
Publicado: (2014)

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model
por: Jit, Mark, et al.
Publicado: (2011)

Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity
por: Brady, Allison M., et al.
Publicado: (2020)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

A case–control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events
por: Geier, David A., et al.
Publicado: (2014)

A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil(®))
por: Govan, Vandana A
Publicado: (2008)

Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials
por: Goldstone, Stephen E.
Publicado: (2023)

Cost-Effectiveness Analysis of the Bivalent and Quadrivalent Human Papillomavirus Vaccines from a Societal Perspective in Colombia
por: Aponte-González, Johanna, et al.
Publicado: (2013)

Prevention of Anal Condyloma with Quadrivalent Human Papillomavirus Vaccination of Older Men Who Have Sex with Men
por: Swedish, Kristin A., et al.
Publicado: (2014)

Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine
por: Schlecht, Nicolas F., et al.
Publicado: (2019)

Resolution of Harada disease-like uveitis after quadrivalent human papillomavirus vaccination: a case report
por: Kong, Kangjie, et al.
Publicado: (2021)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an ontario cohort of grade 8 girls
por: Smith, Leah M, et al.
Publicado: (2011)

Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience
por: Garland, Suzanne M., et al.
Publicado: (2016)

Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1
por: Cespedes, Michelle S., et al.
Publicado: (2018)

A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men
por: Ellsworth, G.B., et al.
Publicado: (2018)

Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study
por: Choi, Hoon
Publicado: (2019)

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study
por: Grein, Ingrid Herta Rotstein, et al.
Publicado: (2020)

Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology
por: Doshi, Peter, et al.
Publicado: (2020)

Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly
por: Kawakami, Kenji, et al.
Publicado: (2018)

No safety signals for GSK quadrivalent influenza vaccine
Publicado: (2022)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
por: Fochesato, Anna, et al.
Publicado: (2022)

Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial
por: Pinto, Ligia A., et al.
Publicado: (2016)

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
por: Moreira, E. D., et al.
Publicado: (2017)

Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case–control assessment of the vaccine adverse event reporting system (VAERS) database
por: Geier, David A., et al.
Publicado: (2016)

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study
por: Haranaka, Miwa, et al.
Publicado: (2023)

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis
por: Kulasingam, Shalini L, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_9787b5voa33cgirvsgihehrsjm